Building A Biosimilars Market: Lessons From The US Launches
Scrip
AmerisourceBergen (ABC) has been involved in launching all three of the currently marketed biosimilars in the US and has a few takeaway messages for manufacturers based on how the US market has responded so far. One of the most important lessons has to do with instilling provider confidence in the biosimilar, according to Rick Lozano, VP of Biosimilars and Integrated Business Development at AmerisourceBergen. "All of these manufacturers are learning that building trust with a provider and trust in a biosimilar is a challenging thing," he commented.
For the full article, visit Scrip.